HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Food Advisory Committee nominations

This article was originally published in The Tan Sheet

Executive Summary

FDA announces two new subcommittees under the FAC - Infant Formula and Nutrition - which have been created "to provide highly specialized expertise in the review and analysis of assigned topics," agency says in Aug. 2 Federal Register notice. Food Advisory Committee was restructured in July 2000 to consist of a "parent" committee and four standing subcommittees (1"The Tan Sheet" July 31, 2000, In Brief). FDA also requests nominations for candidates to fill either current or upcoming committee, subcommittee vacancies...

You may also be interested in...



Food Advisory Committee

FDA requests nominations for candidates to fill either current or upcoming committee vacancies in a July 28 Federal Register notice. In a same-day "Dear Colleague" letter, CFSAN Director Joseph Levitt notes the newly established FAC will consist of a "parent" committee and four standing subcommittees: Dietary Supplements, Additives & Ingredients, Contaminants & Toxicants and Food Biotechnology. The parent committee will be composed of 15 members, including two consumer reps and two non-voting industry reps. Four members will serve as chairs of the subcommittees; each will consist of six standing members serving four-year terms. Six people currently serve on FAC; CFSAN is looking to add up to 29 scientific experts. Nominations can be faxed to FDA at (202) 205-4970

Xbrane Assembles The Troops As FDA Says No To Lucentis Biosimilar

Xbrane Biopharma was riding the crest of a wave with the EU launch of its biosimilar to Lucentis, following years of toil and investment. However, plans to roll out the product in the US will have to be pushed back – likely – into the middle of 2025, following a US FDA complete response letter.

UK MHRA Updates Assistive Tech And Borderline Regulations

Device classification themes were uppermost in April for the UK regulator, which issued key guidance in two areas prone to complexities. It also contributed to the MedTech Directorate’s one-year progress report.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS130812

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel